LCTX Stock - Lineage Cell Therapeutics, Inc.
Unlock GoAI Insights for LCTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $9.50M | $8.95M | $14.70M | $3.90M | $773,000 |
| Gross Profit | $9.16M | $8.27M | $13.97M | $2.47M | $388,000 |
| Gross Margin | 96.5% | 92.5% | 95.0% | 63.4% | 50.2% |
| Operating Income | $-21,478,000 | $-24,733,000 | $-22,520,000 | $-49,211,000 | $-26,447,000 |
| Net Income | $-18,609,000 | $-21,486,000 | $-26,273,000 | $-43,019,000 | $-20,649,000 |
| Net Margin | -195.9% | -240.2% | -178.7% | -1104.2% | -2671.3% |
| EPS | $-0.09 | $-0.12 | $-0.15 | $-0.26 | $-0.14 |
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Visit WebsiteEarnings History & Surprises
LCTXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 9, 2026 | $-0.07 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.02 | $-0.13 | -550.0% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.02 | $-0.01 | +50.0% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.02 | $-0.02 | 0.0% | = MET |
Q1 2025 | Mar 10, 2025 | $-0.04 | $-0.01 | +75.0% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-0.01 | $-0.02 | -53.5% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.02 | $-0.03 | -34.8% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.04 | $-0.04 | -4.4% | ✗ MISS |
Q1 2024 | Mar 7, 2024 | $-0.07 | $-0.03 | +57.1% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.04 | $-0.04 | -6.7% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.02 | $-0.03 | -32.3% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.02 | $-0.03 | -21.8% | ✗ MISS |
Q1 2023 | Mar 9, 2023 | $-0.03 | $-0.03 | -19.2% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.04 | $-0.04 | -14.3% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-0.04 | $-0.04 | -6.7% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.03 | $-0.04 | -17.6% | ✗ MISS |
Q1 2022 | Mar 10, 2022 | $-0.01 | $-0.05 | -264.2% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.05 | $-0.05 | 0.0% | = MET |
Q3 2021 | Aug 12, 2021 | $-0.03 | $-0.03 | -18.2% | ✗ MISS |
Latest News
Frequently Asked Questions about LCTX
What is LCTX's current stock price?
What is the analyst price target for LCTX?
What sector is Lineage Cell Therapeutics, Inc. in?
What is LCTX's market cap?
Does LCTX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to LCTX for comparison